Pfizer stays in the autism drug chase

After a period of silence that followed its much-touted efforts in autism research a few years ago, Pfizer ($PFE) appears to be in the hunt to develop drugs that could address symptoms of the brain disorder. In a mouse study, the drug giant's experimental depression drug GRN-529 reduced visible signs of autism in mice, Bloomberg reported. Pfizer plans further study of the drug after the findings, which were published in Science Translational Medicine. Article